Caris Life Sciences, Inc.
Caris Life Sciences, Inc. Fundamental Analysis
Caris Life Sciences, Inc. (CAI) shows strong financial fundamentals with a PE ratio of -35.73, profit margin of -28.90%, and ROE of 26.98%. The company generates $0.5B in annual revenue with strong year-over-year growth of 34.67%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 39.5/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze CAI's fundamental strength across five key dimensions:
Efficiency Score
WeakCAI struggles to generate sufficient returns from assets.
Valuation Score
ExcellentCAI trades at attractive valuation levels.
Growth Score
ModerateCAI shows steady but slowing expansion.
Financial Health Score
ExcellentCAI maintains a strong and stable balance sheet.
Profitability Score
ModerateCAI maintains healthy but balanced margins.
Key Financial Metrics
Is CAI Expensive or Cheap?
P/E Ratio
CAI trades at -35.73 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, CAI's PEG of -1.85 indicates potential undervaluation.
Price to Book
The market values Caris Life Sciences, Inc. at 11.21 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at -65.97 times EBITDA. This is generally considered low.
How Well Does CAI Make Money?
Net Profit Margin
For every $100 in sales, Caris Life Sciences, Inc. keeps $-28.90 as profit after all expenses.
Operating Margin
Core operations generate -1.41 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $26.98 in profit for every $100 of shareholder equity.
ROA
Caris Life Sciences, Inc. generates $-15.24 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Caris Life Sciences, Inc. generates limited operating cash flow of $38.38M, signaling weaker underlying cash strength.
Free Cash Flow
Caris Life Sciences, Inc. produces free cash flow of $27.21M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.10 in free cash annually.
FCF Yield
CAI converts 0.50% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-35.73
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-1.85
vs 25 benchmark
P/B Ratio
Price to book value ratio
11.21
vs 25 benchmark
P/S Ratio
Price to sales ratio
10.33
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.89
vs 25 benchmark
Current Ratio
Current assets to current liabilities
9.93
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.27
vs 25 benchmark
ROA
Return on assets percentage
-0.15
vs 25 benchmark
ROCE
Return on capital employed
-0.01
vs 25 benchmark
How CAI Stacks Against Its Sector Peers
| Metric | CAI Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -35.73 | 29.43 | Better (Cheaper) |
| ROE | 26.98% | 800.00% | Weak |
| Net Margin | -28.90% | -20145.00% (disorted) | Weak |
| Debt/Equity | 0.89 | 0.30 | Weak (High Leverage) |
| Current Ratio | 9.93 | 4.64 | Strong Liquidity |
| ROA | -15.24% | -17936.00% (disorted) | Weak |
CAI outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Caris Life Sciences, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-93.00%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
-164.29%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-106.83%
Industry Style: Defensive, Growth, Innovation
Declining